Impact of repetitive transcranial magnetic stimulation on generalized anxiety disorder in treatment-resistant depression

C. Griffiths, A. O'Neill-Kerr, R. De Vai , Ksenija Maravic da Silva

Research output: Contribution to journalArticle

Abstract

Background: Published evidence indicates the value of repetitive transcranial magnetic stimulation (rTMS) for generalized anxiety disorder in patients with treatment-resistant depression (TRD). As a part of routine clinical service, patients with TRD received right dorsolateral prefrontal cortex (DLPFC) inhibitory rTMS immediately prior to left DLPFC depression treatment delivered according to a US Food and Drug Administration protocol.

Methods: A retrospective investigation of routinely collected data between 2016 and 2018 was undertaken. Measures used were the clinician rated Clinical Global Impressions–Severity (CGI-S) scale and Hamilton Depression Rating scale (HAM-D), and the patient-rated Generalized Anxiety Disorder scale–7 (GAD-7) and Patient Health Questionnaire (PHQ-9). The outcome data of 61 patients with TRD were analyzed. The sample included patients with comorbid psychiatric diagnoses.

Results: Response and remission rates, respectively, were 17.1% and 27.3% on the GAD-7; 20.7% and 12.5% on the HAM-D; 19% and 24% on the PHQ-9; and 20% and 23.5% on the CGI-S. Post-treatment scores significantly improved on the GAD-7, HAM-D, and CGI-S scales, with medium to large effect sizes (.61, .62, and .86 respectively).

Conclusions: Results indicate the potential value of rTMS in treating anxiety in patients who are referred for rTMS for TRD. Well-designed and adequately powered randomized controlled trials are required to determine clinical recommendations.
Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalAnnals of Clinical Psychiatry
Volume31
Issue number4
Publication statusPublished - Nov 2019
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Transcranial Magnetic Stimulation
Anxiety Disorders
Prefrontal Cortex
Depression
United States Food and Drug Administration
Mental Disorders
Anxiety
Randomized Controlled Trials
Health
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Impact of repetitive transcranial magnetic stimulation on generalized anxiety disorder in treatment-resistant depression. / Griffiths, C.; O'Neill-Kerr, A.; De Vai , R.; Maravic da Silva, Ksenija.

In: Annals of Clinical Psychiatry, Vol. 31, No. 4, 11.2019, p. 236-241.

Research output: Contribution to journalArticle

@article{0b5f421fe7c648a6ba492b78617b1ca2,
title = "Impact of repetitive transcranial magnetic stimulation on generalized anxiety disorder in treatment-resistant depression",
abstract = "Background: Published evidence indicates the value of repetitive transcranial magnetic stimulation (rTMS) for generalized anxiety disorder in patients with treatment-resistant depression (TRD). As a part of routine clinical service, patients with TRD received right dorsolateral prefrontal cortex (DLPFC) inhibitory rTMS immediately prior to left DLPFC depression treatment delivered according to a US Food and Drug Administration protocol.Methods: A retrospective investigation of routinely collected data between 2016 and 2018 was undertaken. Measures used were the clinician rated Clinical Global Impressions–Severity (CGI-S) scale and Hamilton Depression Rating scale (HAM-D), and the patient-rated Generalized Anxiety Disorder scale–7 (GAD-7) and Patient Health Questionnaire (PHQ-9). The outcome data of 61 patients with TRD were analyzed. The sample included patients with comorbid psychiatric diagnoses.Results: Response and remission rates, respectively, were 17.1{\%} and 27.3{\%} on the GAD-7; 20.7{\%} and 12.5{\%} on the HAM-D; 19{\%} and 24{\%} on the PHQ-9; and 20{\%} and 23.5{\%} on the CGI-S. Post-treatment scores significantly improved on the GAD-7, HAM-D, and CGI-S scales, with medium to large effect sizes (.61, .62, and .86 respectively).Conclusions: Results indicate the potential value of rTMS in treating anxiety in patients who are referred for rTMS for TRD. Well-designed and adequately powered randomized controlled trials are required to determine clinical recommendations.",
author = "C. Griffiths and A. O'Neill-Kerr and {De Vai}, R. and {Maravic da Silva}, Ksenija",
year = "2019",
month = "11",
language = "English",
volume = "31",
pages = "236--241",
journal = "Annals of Clinical Psychiatry",
number = "4",

}

TY - JOUR

T1 - Impact of repetitive transcranial magnetic stimulation on generalized anxiety disorder in treatment-resistant depression

AU - Griffiths, C.

AU - O'Neill-Kerr, A.

AU - De Vai , R.

AU - Maravic da Silva, Ksenija

PY - 2019/11

Y1 - 2019/11

N2 - Background: Published evidence indicates the value of repetitive transcranial magnetic stimulation (rTMS) for generalized anxiety disorder in patients with treatment-resistant depression (TRD). As a part of routine clinical service, patients with TRD received right dorsolateral prefrontal cortex (DLPFC) inhibitory rTMS immediately prior to left DLPFC depression treatment delivered according to a US Food and Drug Administration protocol.Methods: A retrospective investigation of routinely collected data between 2016 and 2018 was undertaken. Measures used were the clinician rated Clinical Global Impressions–Severity (CGI-S) scale and Hamilton Depression Rating scale (HAM-D), and the patient-rated Generalized Anxiety Disorder scale–7 (GAD-7) and Patient Health Questionnaire (PHQ-9). The outcome data of 61 patients with TRD were analyzed. The sample included patients with comorbid psychiatric diagnoses.Results: Response and remission rates, respectively, were 17.1% and 27.3% on the GAD-7; 20.7% and 12.5% on the HAM-D; 19% and 24% on the PHQ-9; and 20% and 23.5% on the CGI-S. Post-treatment scores significantly improved on the GAD-7, HAM-D, and CGI-S scales, with medium to large effect sizes (.61, .62, and .86 respectively).Conclusions: Results indicate the potential value of rTMS in treating anxiety in patients who are referred for rTMS for TRD. Well-designed and adequately powered randomized controlled trials are required to determine clinical recommendations.

AB - Background: Published evidence indicates the value of repetitive transcranial magnetic stimulation (rTMS) for generalized anxiety disorder in patients with treatment-resistant depression (TRD). As a part of routine clinical service, patients with TRD received right dorsolateral prefrontal cortex (DLPFC) inhibitory rTMS immediately prior to left DLPFC depression treatment delivered according to a US Food and Drug Administration protocol.Methods: A retrospective investigation of routinely collected data between 2016 and 2018 was undertaken. Measures used were the clinician rated Clinical Global Impressions–Severity (CGI-S) scale and Hamilton Depression Rating scale (HAM-D), and the patient-rated Generalized Anxiety Disorder scale–7 (GAD-7) and Patient Health Questionnaire (PHQ-9). The outcome data of 61 patients with TRD were analyzed. The sample included patients with comorbid psychiatric diagnoses.Results: Response and remission rates, respectively, were 17.1% and 27.3% on the GAD-7; 20.7% and 12.5% on the HAM-D; 19% and 24% on the PHQ-9; and 20% and 23.5% on the CGI-S. Post-treatment scores significantly improved on the GAD-7, HAM-D, and CGI-S scales, with medium to large effect sizes (.61, .62, and .86 respectively).Conclusions: Results indicate the potential value of rTMS in treating anxiety in patients who are referred for rTMS for TRD. Well-designed and adequately powered randomized controlled trials are required to determine clinical recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85074553837&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 236

EP - 241

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

IS - 4

ER -